Sight Sciences, Inc. 8-K

What Happened
Sight Sciences, Inc. (SGHT) announced in an 8-K/press release (filed March 30, 2026) that the U.S. District Court for the District of Delaware entered an order on March 27, 2026 preserving a jury’s verdict that Alcon willfully infringed three Sight Sciences patents in litigation that began in September 2021. The Court preserved a monetary award of $34 million for past infringement (plus supplemental damages and interest) and an ongoing royalty of 10% of Hydrus® Microstent revenue through November 10, 2028. A final judgment is expected after supplemental damages and pre-judgment interest are calculated; that judgment is subject to appeal by Alcon.

Key Details

• Lawsuit filed: September 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc.
• Patents asserted: U.S. Patent Nos. 8,287,482; 9,370,443; 11,389,328.
• Court order date: March 27, 2026; press release/8-K filed March 30, 2026.
• Award: $34 million for past infringement, plus supplemental damages and interest; ongoing royalty = 10% of Hydrus revenue through 11/10/2028.
• Appeals and challenges: Alcon may appeal; Alcon filed ex parte reexamination petitions with the USPTO in June 2025 and the USPTO is reexamining the asserted claims. Previous inter partes review petitions by Alcon were denied in March 2023 for two of the patents.

Why It Matters
This is material for investors because the order preserves a significant jury verdict that could produce multi-million-dollar damages and future royalty revenue if appeals and USPTO reexamination do not overturn the outcome. However, the company cannot collect damages until appeals and any related USPTO proceedings are resolved or expire, and adverse USPTO or appellate decisions could reduce or eliminate recoverable amounts. The situation creates both potential near-term valuation impact (legal risk resolution) and ongoing revenue exposure tied to Alcon’s Hydrus sales through late 2028.